Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Feb;211(2):144-146.
doi: 10.1164/rccm.202409-1681ED.

Best in Class: IgG as a Treatable Trait for Exacerbation Prevention in Chronic Obstructive Pulmonary Disease

Carolyn J Wang  1 , Don D Sin  1   2
Affiliations
Editorial

Best in Class: IgG as a Treatable Trait for Exacerbation Prevention in Chronic Obstructive Pulmonary Disease

Carolyn J Wang et al. Am J Respir Crit Care Med. 2025 Feb.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Proposed mechanisms for IgG deficiency and chronic obstructive pulmonary disease exacerbations. The risk of exacerbations is associated with reduced IgG, where (A) low IgG increases susceptibility to infiltration of viral/bacterial pathogens, leading to (B) airway inflammation (8). (C) Recurrent infection with subsequent inflammation may result in airway remodeling (11). Created with BioRender.com.
See this image and copyright information in PMC

Comment on

  • Serum Immunoglobulin G Levels Are Associated with Risk for Exacerbations: An Analysis of SPIROMICS.
    Burnim M, Putcha N, LaFon D, Woo H, Azar A, Groenke L, Stampfli M, Schaub A, Fawzy A, Balasubramanian A, Fedarko N, Cooper CB, Bowler RP, Comellas A, Krishnan JA, Han MK, Couper D, Peters SP, Drummond MB, O'Neal W, Paine R, Criner G, Martinez FJ, Curtis JL, Barr G, Huang YJ, Woodruff P, Dransfield M, Hansel NN. Burnim M, et al. Am J Respir Crit Care Med. 2025 Feb;211(2):215-221. doi: 10.1164/rccm.202311-2184OC. Am J Respir Crit Care Med. 2025. PMID: 39441116

References

    1. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. Am J Respir Crit Care Med . 2017;195:557–582. - PubMed
    1. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med . 2006;173:1114–1121. - PubMed
    1. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JAD, Jr, Criner GJ, et al. COPD Clinical Research Network Azithromycin for prevention of exacerbations of COPD. N Engl J Med . 2011;365:689–698. - PMC - PubMed
    1. Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, et al. NOTUS Study Investigators Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation. N Engl J Med . 2024;390:2274–2283. - PubMed
    1. Leitao Filho FS, Ra SW, Mattman A, Schellenberg RS, Criner GJ, Woodruff PG, et al. Canadian Respiratory Research Network (CRRN) Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD. Respir Res . 2018;19:30. - PMC - PubMed

LinkOut - more resources